title: ÐÐ¾Ð»Ð¸ÑÐµÑÑÐ²ÐµÐ½Ð½ÑÐ¹ Ð°Ð½Ð°Ð»Ð¸Ð· ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð¾Ð² Ð´Ð»Ñ Ð¾ÑÐµÐ½ÐºÐ¸ Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ ÑÑÐ°ÑÑÑÐ° Ð¶Ð¸ÑÐ¾Ð²Ð¾Ð¹ ÑÐºÐ°Ð½Ð¸ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸ÐµÐ¼ Ð¸ ÑÐ°Ñ Ð°ÑÐ½ÑÐ¼ Ð´Ð¸Ð°Ð±ÐµÑÐ¾Ð¼ 2 ÑÐ¸Ð¿Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Quantitative gene expression analysis to assess the immunological status of adipose tissue in patients with obesity and type 2 diabetes mellitus
Creators: name: Ð¡ÑÑÑÑÐºÐ¾Ð²Ð°, ÐÐ°ÑÐ¸Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸Ðµ
Ñ ÑÐ¾Ð½Ð¸ÑÐµÑÐºÐ¾Ðµ Ð²ÑÐ»Ð¾ÑÐµÐºÑÑÐµÐµ Ð²Ð¾ÑÐ¿Ð°Ð»ÐµÐ½Ð¸Ðµ
Ð¸Ð½ÑÑÐ»Ð¸Ð½Ð¾ÑÐµÐ·Ð¸ÑÑÐµÐ½ÑÐ½Ð¾ÑÑÑ
ÑÐ°Ñ Ð°ÑÐ½ÑÐ¹ Ð´Ð¸Ð°Ð±ÐµÑ 2 ÑÐ¸Ð¿Ð°
Ð¿Ð¾Ð´ÐºÐ¾Ð¶Ð½Ð°Ñ Ð¶Ð¸ÑÐ¾Ð²Ð°Ñ ÑÐºÐ°Ð½Ñ
Ð²Ð¸ÑÑÐµÑÐ°Ð»ÑÐ½Ð°Ñ Ð¶Ð¸ÑÐ¾Ð²Ð°Ñ ÑÐºÐ°Ð½Ñ
ÑÐµÐ³ÑÐ»ÑÑÐ¾ÑÐ½ÑÐµ Ð¢-Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÑ
obesity
chronic low-grade inflammation
insulin resistance
type 2 diabetes mellitus
subcutaneous adipose tissue
visceral adipose tissue
regulatory T lymphocytes

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° ÑÑÐ°Ð²Ð½Ð¸ÑÐµÐ»ÑÐ½Ð¾Ð¼Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ñ ÑÑÐ¾Ð²Ð½ÐµÐ¹ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð¾Ð² CD25 (IL-2RÎ±), FOXP3, IL10, GATA3, SOCS1, LRRC32 Ð¸ IKZF2, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð¼Ð¾Ð³ÑÑ Ð¾ÑÑÐ°Ð¶Ð°ÑÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ Treg-ÐºÐ»ÐµÑÐ¾Ðº, Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸ÐµÐ¼ Ñ/Ð±ÐµÐ· Ð¡Ð2 Ð¸ Ñ Ð»Ð¸Ñ Ñ Ð½Ð¾ÑÐ¼Ð°Ð»ÑÐ½Ð¾Ð¹ Ð¼Ð°ÑÑÐ¾Ð¹ ÑÐµÐ»Ð°. ÐÑÐ»Ð¸ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ñ Ð¾Ð±ÑÐ°Ð·ÑÑ ÐÐÐ¢ Ð¸ ÐÐÐ¢ 53 Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸ÐµÐ¼ (Ð¸Ð· Ð½Ð¸Ñ 27 Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ð±ÐµÐ· Ð¡Ð2 Ð¸ 26 â Ñ Ð¡Ð2) Ð¸ 15 Ð»Ð¸Ñ Ð³ÑÑÐ¿Ð¿Ñ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ñ. ÐÑÐµÐ½ÐºÐ° ÑÑÐ¾Ð²Ð½ÐµÐ¹ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð¾Ð² Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð°ÑÑ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ ÐÐ¦Ð  Ð² ÑÐµÐ¶Ð¸Ð¼Ðµ ÑÐµÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð²ÑÐµÐ¼ÐµÐ½Ð¸. Ð£ÑÐ¾Ð²Ð½Ð¸ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° CD25 (IL-2RÎ±) Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ð¸ Ð³ÐµÐ½Ð° IL10 Ð² ÐÐÐ¢ Ð±ÑÐ»Ð¸ Ð¿Ð¾Ð²ÑÑÐµÐ½Ñ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ/Ð±ÐµÐ· Ð¡Ð2. ÐÑÐ¸ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸Ð¸ Ð¸ Ð¡Ð2 Ð½Ð°Ð±Ð»ÑÐ´Ð°Ð»Ð°ÑÑ Ð¿Ð¾Ð²ÑÑÐµÐ½Ð½Ð°Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ñ Ð³ÐµÐ½Ð¾Ð² LRRC32 Ð¸ FOXP3 Ð² ÐÐÐ¢ Ð¸ Ð³ÐµÐ½Ð° SOCS1 Ð² ÐÐÐ¢. ÐÐ¾ÐºÐ°Ð·Ð°Ð½Ð¾ ÑÐ²ÐµÐ»Ð¸ÑÐµÐ½Ð¸Ðµ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð¾Ð² GATA3 Ð¸ SOCS1 Ð² ÐÐÐ¢ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸ÐµÐ¼. ÐÐµ Ð±ÑÐ»Ð¾ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¾ Ð·Ð½Ð°ÑÐ¸Ð¼ÑÑ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸Ð¹ Ð² ÑÑÐ¾Ð²Ð½ÑÑ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° IKZF2 Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ð¸ ÐºÐ¾Ð½ÑÑÐ¾Ð»Ñ. Ð Ð¾Ð±ÑÐµÐ¹ Ð²ÑÐ±Ð¾ÑÐºÐµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ð¿ÑÐ¾ÑÐ»ÐµÐ¶Ð¸Ð²Ð°Ð»Ð¸ÑÑ ÐºÐ¾ÑÑÐµÐ»ÑÑÐ¸Ð¸ ÑÑÐ¾Ð²Ð½ÐµÐ¹ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð¾Ð² GATA3, LRRC32, FOXP3, IL10 Ð¸ SOCS1 Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ñ Ð¼ÐµÑÐ°Ð±Ð¾Ð»Ð¸ÑÐµÑÐºÐ¸Ð¼Ð¸ Ð¿Ð°ÑÐ°Ð¼ÐµÑÑÐ°Ð¼Ð¸. Ð ÐµÐ·ÑÐ»ÑÑÐ°ÑÑ ÑÐ°Ð±Ð¾ÑÑ Ð¿Ð¾Ð·Ð²Ð¾Ð»Ð¸Ð»Ð¸ ÑÐ´ÐµÐ»Ð°ÑÑ Ð²ÑÐ²Ð¾Ð´, ÑÑÐ¾ Ð¿ÑÐ¾ÑÐ¸Ð»Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð²ÑÐµÑ Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÑ Ð³ÐµÐ½Ð¾Ð², Ð·Ð° Ð¸ÑÐºÐ»ÑÑÐµÐ½Ð¸ÐµÐ¼ IKZF2, Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ð°ÑÑÐ¾ÑÐ¸Ð¸ÑÐ¾Ð²Ð°Ð½ Ñ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸ÐµÐ¼ Ð¸ Ð¡Ð2. ÐÐ»Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Treg Ð¿ÑÐ¸ Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸ÑÐµÐ»ÑÐ½ÑÑ Ð¿ÑÐ¾ÑÐµÑÑÐ°Ñ Ð² Ð¶Ð¸ÑÐ¾Ð²Ð¾Ð¹ ÑÐºÐ°Ð½Ð¸ Ð¸ Ð½Ð°ÑÑÑÐµÐ½Ð¸ÑÑ ÑÐ³Ð»ÐµÐ²Ð¾Ð´Ð½Ð¾Ð³Ð¾ Ð¾Ð±Ð¼ÐµÐ½Ð° ÑÑÐµÐ±ÑÑÑÑÑ Ð´Ð°Ð»ÑÐ½ÐµÐ¹ÑÐ¸Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ.
description: The given work is devoted to a comparative analysis of the expression level of the genes CD25 (IL-2RÎ±), FOXP3, IL10, GATA3, SOCS1, LRRC32 and IKZF2, which may reflect the activity of Treg cells, in SAT and VAT in obese patients with/without T2DM and in with normal body weight. Samples of SAT and VAT from 53 obese patients (of which 27 patients without T2DM and 26 with T2DM) and 15 individuals from the comparison group were studied. The level of mRNA of genes was estimated by real-time PCR. The mRNA levels of the CD25 (IL-2RÎ±) gene in SAT and VAT and the IL10 gene in SAT were increased in patients with/without T2DM. In obesity and T2DM increased expression of the LRRC32 and FOXP3 genes in SAT and the SOCS1 gene in VAT were observed. An increase in the expression of the GATA3 and SOCS1 genes in SAT in obese patients was shown. There were no significant changes in the IKZF2 gene mRNA level in SAT and VAT in patients and controls. In the general sample of patients correlations of the expression levels of the GATA3, LRRC32, FOXP3, IL10 and SOCS1 genes in SAT and VAT with metabolic parameters were traced. The results of the work allowed us to conclude that the expression profile of all studied genes, except for IKZF2, in SAT and VAT is associated with obesity and T2DM. Further studies are required to determine Treg activity during inflammatory processes in adipose tissue and carbohydrate metabolism disorders.